These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

535 related articles for article (PubMed ID: 27893852)

  • 1. A Comparative Study of SMN Protein and mRNA in Blood and Fibroblasts in Patients with Spinal Muscular Atrophy and Healthy Controls.
    Wadman RI; Stam M; Jansen MD; van der Weegen Y; Wijngaarde CA; Harschnitz O; Sodaar P; Braun KP; Dooijes D; Lemmink HH; van den Berg LH; van der Pol WL
    PLoS One; 2016; 11(11):e0167087. PubMed ID: 27893852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A sensitive assay for measuring SMN mRNA levels in peripheral blood and in muscle samples of patients affected with spinal muscular atrophy.
    Vezain M; Saugier-Veber P; Melki J; Toutain A; Bieth E; Husson M; Pedespan JM; Viollet L; Pénisson-Besnier I; Fehrenbach S; Bou J; Frébourg T; Tosi M
    Eur J Hum Genet; 2007 Oct; 15(10):1054-62. PubMed ID: 17609673
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biomarker for Spinal Muscular Atrophy: Expression of SMN in Peripheral Blood of SMA Patients and Healthy Controls.
    Czech C; Tang W; Bugawan T; Mano C; Horn C; Iglesias VA; Fröhner S; Zaworski PG; Paushkin S; Chen K; Kremer T
    PLoS One; 2015; 10(10):e0139950. PubMed ID: 26468953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of SMN protein, transcript, and copy number in the biomarkers for spinal muscular atrophy (BforSMA) clinical study.
    Crawford TO; Paushkin SV; Kobayashi DT; Forrest SJ; Joyce CL; Finkel RS; Kaufmann P; Swoboda KJ; Tiziano D; Lomastro R; Li RH; Trachtenberg FL; Plasterer T; Chen KS;
    PLoS One; 2012; 7(4):e33572. PubMed ID: 22558076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The oral splicing modifier RG7800 increases full length survival of motor neuron 2 mRNA and survival of motor neuron protein: Results from trials in healthy adults and patients with spinal muscular atrophy.
    Kletzl H; Marquet A; Günther A; Tang W; Heuberger J; Groeneveld GJ; Birkhoff W; Mercuri E; Lochmüller H; Wood C; Fischer D; Gerlach I; Heinig K; Bugawan T; Dziadek S; Kinch R; Czech C; Khwaja O
    Neuromuscul Disord; 2019 Jan; 29(1):21-29. PubMed ID: 30553700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic and expression studies of SMN2 gene in Russian patients with spinal muscular atrophy type II and III.
    Zheleznyakova GY; Kiselev AV; Vakharlovsky VG; Rask-Andersen M; Chavan R; Egorova AA; Schiöth HB; Baranov VS
    BMC Med Genet; 2011 Jul; 12():96. PubMed ID: 21762474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SMN mRNA and protein levels in peripheral blood: biomarkers for SMA clinical trials.
    Sumner CJ; Kolb SJ; Harmison GG; Jeffries NO; Schadt K; Finkel RS; Dreyfuss G; Fischbeck KH
    Neurology; 2006 Apr; 66(7):1067-73. PubMed ID: 16481599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative analyses of SMN1 and SMN2 based on real-time lightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy.
    Feldkötter M; Schwarzer V; Wirth R; Wienker TF; Wirth B
    Am J Hum Genet; 2002 Feb; 70(2):358-68. PubMed ID: 11791208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intragenic mutations in SMN1 may contribute more significantly to clinical severity than SMN2 copy numbers in some spinal muscular atrophy (SMA) patients.
    Yamamoto T; Sato H; Lai PS; Nurputra DK; Harahap NI; Morikawa S; Nishimura N; Kurashige T; Ohshita T; Nakajima H; Yamada H; Nishida Y; Toda S; Takanashi J; Takeuchi A; Tohyama Y; Kubo Y; Saito K; Takeshima Y; Matsuo M; Nishio H
    Brain Dev; 2014 Nov; 36(10):914-20. PubMed ID: 24359787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and molecular cross-sectional study of a cohort of adult type III spinal muscular atrophy patients: clues from a biomarker study.
    Tiziano FD; Lomastro R; Di Pietro L; Barbara Pasanisi M; Fiori S; Angelozzi C; Abiusi E; Angelini C; Sorarù G; Gaiani A; Mongini T; Vercelli L; Vasco G; Vita G; Luca Vita G; Messina S; Politano L; Passamano L; Di Gregorio G; Montomoli C; Orsi C; Campanella A; Mantegazza R; Morandi L
    Eur J Hum Genet; 2013 Jun; 21(6):630-6. PubMed ID: 23073312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of spinal muscular atrophy cells with drugs that upregulate SMN expression reveals inter- and intra-patient variability.
    Also-Rallo E; Alías L; Martínez-Hernández R; Caselles L; Barceló MJ; Baiget M; Bernal S; Tizzano EF
    Eur J Hum Genet; 2011 Oct; 19(10):1059-65. PubMed ID: 21610752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutics development for spinal muscular atrophy.
    Sumner CJ
    NeuroRx; 2006 Apr; 3(2):235-45. PubMed ID: 16554261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation between SMN2 copy number and clinical phenotype of spinal muscular atrophy: three SMN2 copies fail to rescue some patients from the disease severity.
    Harada Y; Sutomo R; Sadewa AH; Akutsu T; Takeshima Y; Wada H; Matsuo M; Nishio H
    J Neurol; 2002 Sep; 249(9):1211-9. PubMed ID: 12242541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Accuracy of marker analysis, quantitative real-time polymerase chain reaction, and multiple ligation-dependent probe amplification to determine SMN2 copy number in patients with spinal muscular atrophy.
    Alías L; Bernal S; Barceló MJ; Also-Rallo E; Martínez-Hernández R; Rodríguez-Alvarez FJ; Hernández-Chico C; Baiget M; Tizzano EF
    Genet Test Mol Biomarkers; 2011 Sep; 15(9):587-94. PubMed ID: 21548796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hydroxyurea enhances SMN2 gene expression in spinal muscular atrophy cells.
    Grzeschik SM; Ganta M; Prior TW; Heavlin WD; Wang CH
    Ann Neurol; 2005 Aug; 58(2):194-202. PubMed ID: 16049920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LBH589 induces up to 10-fold SMN protein levels by several independent mechanisms and is effective even in cells from SMA patients non-responsive to valproate.
    Garbes L; Riessland M; Hölker I; Heller R; Hauke J; Tränkle C; Coras R; Blümcke I; Hahnen E; Wirth B
    Hum Mol Genet; 2009 Oct; 18(19):3645-58. PubMed ID: 19584083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SMN2 and NAIP gene dosages in Vietnamese patients with spinal muscular atrophy.
    Tran VK; Sasongko TH; Hong DD; Hoan NT; Dung VC; Lee MJ; Gunadi ; Takeshima Y; Matsuo M; Nishio H
    Pediatr Int; 2008 Jun; 50(3):346-51. PubMed ID: 18533950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The benzamide M344, a novel histone deacetylase inhibitor, significantly increases SMN2 RNA/protein levels in spinal muscular atrophy cells.
    Riessland M; Brichta L; Hahnen E; Wirth B
    Hum Genet; 2006 Aug; 120(1):101-10. PubMed ID: 16724231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The analysis of the association between the copy numbers of survival motor neuron gene 2 and neuronal apoptosis inhibitory protein genes and the clinical phenotypes in 40 patients with spinal muscular atrophy: Observational study.
    Zhang Y; He J; Zhang Y; Li L; Tang X; Wang L; Guo J; Jin C; Tighe S; Zhang Y; Zhu Y; Zhu B
    Medicine (Baltimore); 2020 Jan; 99(3):e18809. PubMed ID: 32011487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Securinine enhances SMN2 exon 7 inclusion in spinal muscular atrophy cells.
    Chen YC; Chang JG; Liu TY; Jong YJ; Cheng WL; Yuo CY
    Biomed Pharmacother; 2017 Apr; 88():708-714. PubMed ID: 28152480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.